文献速递细菌感染、耐药与抗菌药物医院感染防控

COVID-19大流行后铜绿假单胞菌菌血症耐药性下降:纵向观察研究

Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

MDRPA比例从大流行前的21%(62/291)降至大流行后的9%(19/202)(调整OR 0.38,95%CI 0.18-0.79,p=0.01)。MDRPA菌血症患者总体住院死亡率仍高达28%,两个时期之间无实质性差异。

要点

  • MDRPA比例从大流行前21%(62/291)降至大流行后9%(19/202)。
  • 调整年龄、性别和ICU治疗后,调整OR 0.38(95%CI 0.18-0.79,p=0.01)。
  • MDRPA菌血症患者总体住院死亡率为28%,两个时期之间无实质性差异。

核心结论

  • 观察到COVID-19大流行开始后MDRPA发生率下降,可能由感染控制措施加强、抗菌药物使用变化和患者人群变化驱动。

主要发现

  • MDRPA比例从大流行前的21%(62/291)降至大流行后的9%(19/202)(调整OR 0.38,95%CI 0.18-0.79,p=0.01)。
  • 初始非MDRPA菌血症后住院期间发生MDRPA罕见,且不太可能早于2周后发生。
  • 大流行开始后,未观察到涉及心血管或肺部疾病的MDRPA病例,烧伤或器官移植患者中MDRPA病例显著减少。
  • 大流行开始后环丙沙星和妥布霉素使用显著下降。
  • MDRPA菌血症患者总体住院死亡率为28%,两个时期之间无实质性差异。

关键数值与推荐

  • MDR定义为对5类抗菌药物中至少3类耐药。

临床怎么用

  • 研究结果可能为铜绿假单胞菌菌血症的临床管理提供参考。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Understanding the effects of changes brought by the COVID-19 pandemic on antimicrobial resistance in P. aeruginosa (PA) is essential to inform clinical management. METHODS: This single-centre retrospective cohort study included adult inpatients with PA bacteraemia at the University Hospital Zurich between January 2014 and December 2023. The primary outcome was the association between the start of the COVID-19 pandemic and PA with multidrug resistance (MDR), defined as resistance to ≥3 of 5 antibiotic classes. We used logistic regression to adjust for age, sex and ICU treatment. Secondary outcomes included changes in resistance patterns, patient demographics and antimicrobial consumption. RESULTS: A total of 493 instances of PA bacteraemia in 333 patients were observed during the study period. The proportion of MDRPA declined from 21% (62/291) pre-pandemic to 9% (19/202) post-pandemic (adjusted OR 0.38, 95% CI 0.18-0.79, p = 0.01). The occurrence of MDRPA during hospitalization following an initial instance of non-MDRPA bacteraemia was rare and unlikely to happen earlier than after 2 weeks. After the start of the pandemic, we observed no MDRPA cases involving cardiovascular or pulmonary diseases and marked reductions in patients with burn injuries or organ transplants. Furthermore, ciprofloxacin and tobramycin use significantly decreased after the start of the pandemic. Overall in-hospital mortality among patients with MDRPA bacteraemia remained high (28%), with no substantial differences between time periods. CONCLUSION: We observed a decline in MDRPA occurrence after the start of the COVID-19 pandemic, possibly driven by intensified infection control measures, shifts in antimicrobial use and changes in patient populations.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Butscheid Y, Frey PM, Pfister M, et al. Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study. J Antimicrob Chemother. 2025. PMID: 40366637. doi:10.1093/jac/dkaf136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。